Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation

Hackensack, NJ – November 2, 2011 – Champions Oncology, Inc. (“Champions” or the “Company”) (OTC Bulletin Board: CSBR) , a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, has appointed Gary G. Gemignani to the Company’s management team, as Executive Vice President and Chief Financial Officer. Joel Ackerman, the Company’s Chief Executive Officer, served as interim Chief Financial Officer, until Mr. Gemignani’s appointment. Mr. Ackerman commented “We are pleased to add an executive with Gary’s background and vast experiences as we continue to build our management team.”

Most recently, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Coronado Biosciences, a company focused on novel immunotherapy agents for cancer and inflammatory diseases. From June 2005 through March 2010, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer for Gentium S.p.A., a biotechnology company focused on developing products to address complications of cancer therapy. Prior to that Mr. Gemignani held management positions of increasing responsibility at Wyeth, Novartis and Prudential Financial. Mr. Gemignani received a Bachelor’s Degree in Accounting from St. Peter’s College.

Additionally, Champions announces the relocation of its corporate office from Baltimore, MD to Hackensack, NJ.